ZG-2305 is a potent, orally active and selective factor inhibiting hypoxia-inducible factor (FIH) inhibitor with Ki values of 79.6, 2786 nM for FIH, PHD2, respectively. ZG-2305 increases the expression of EGLN3 gene. ZG-2305 decreases the cellular triglycerides levels and reduces lipid accumulation. ZG-2305 has the potential for the research of obesity and fatty liver disease[1].